EUCTR2016-000155-28-DK进行中（未招募）1 期
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 compared to PT005 in Subjects With Moderate to Very Severe COPD - SOPHOS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,843
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria:
- •1. Give their signed written informed consent to participate
- •2. At least 40 years of age and no older than 80 years of age
- •3. Moderate to Very Severe COPD patients who are symptomatic
- •4. Must be receiving one or more inhaled bronchodilators as maintenance therapy
- •5. Must have a documented history of COPD exacerbations
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1023
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 837
排除标准
- •Exclusion Criteria:
- •1.Current diagnosis of asthma
- •2.COPD due to a1-Antitrypsin Deficiency
- •3. Known active tuberculosis, lung cancer, cystic fibrosis, and significant bronchiectasis, Pulmonary resection or Lung Volume Reduction Surgery during the past 6 months.
- •4. Long-term-oxygen therapy (= 15 hours a day).
研究者
相似试验
进行中（未招募）
1 期
Study of Lung Function and Health Outcome Improvement in Obstructive Lung DiseaseModerate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 20.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2016-000154-34-DEAstraZeneca AB2,420
进行中（未招募）
1 期
A Randomized, Double-Blind, Parallel Group, Multi-Center 24 Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent AsthmaSubjects With Persistent AsthmaEUCTR2020-000532-22-Outside-EU/EEAPearl Therapeutics Inc.1,071
招募中
1 期
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)CTIS2023-507407-59-00Astrazeneca AB5,000
进行中（未招募）
1 期
Study of Lung Function and Health Outcome Improvement in Obstructive Lung DiseaseEUCTR2016-000154-34-CZPearl Therapeutics, Inc.2,420
进行中（未招募）
1 期
A Study to Assess the Efficacy and Safety of PT009 compared to PT005 onCOPD Exacerbations over a 52-Week Period in Subjects with Moderate toVery Severe COPD (sophos)Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 19.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2016-000155-28-ESPearl Therapeutics, Inc. (Pearl)2,241